Ishaq Musarat, Hu Jiajie, Wu Xiaoyun, Fu Qiong, Yang Yalin, Liu Qingzhen, Guo Deyin
State Key Laboratory of Virology and Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan, China.
Mol Biotechnol. 2008 Jul;39(3):231-8. doi: 10.1007/s12033-008-9040-0. Epub 2008 Feb 8.
The targeting of a cellular co-factor, rather than the HIV-1-specific RNAs, by small interfering RNAs holds promise as the rapid mutational ability of the HIV-1 genome may obviate the potential clinical use of RNAi against this virus. The DEAD-box RNA helicase DDX3 is an essential Rev co-factor in the CRM1-Rev-RRE complex that promotes the export of unspliced and single-spliced HIV-1 RNAs from the nucleus to cytoplasm. In this report, human DDX3 was targeted by specific short hairpin RNAs, and the down-regulation of cell's endogenous DDX3 suppressed the nuclear export of unspliced HIV-1 RNAs but did not affect the cell viability. We further showed that the knockdown of cellular DDX3 could effectively inhibit the replication of HIV-1. Therefore, the current results suggest that the RNA helicase DDX3 may become a potential target by RNAi for future genetic therapy of HIV/AIDS.
通过小分子干扰RNA靶向细胞辅助因子而非HIV-1特异性RNA具有前景,因为HIV-1基因组的快速突变能力可能使RNA干扰针对该病毒的潜在临床应用无效。DEAD盒RNA解旋酶DDX3是CRM1-Rev-RRE复合物中Rev的必需辅助因子,该复合物促进未剪接和单剪接的HIV-1 RNA从细胞核输出到细胞质。在本报告中,通过特异性短发夹RNA靶向人DDX3,细胞内源性DDX3的下调抑制了未剪接的HIV-1 RNA的核输出,但不影响细胞活力。我们进一步表明,细胞DDX3的敲低可有效抑制HIV-1的复制。因此,目前的结果表明,RNA解旋酶DDX3可能成为RNA干扰未来用于HIV/AIDS基因治疗的潜在靶点。